Travere Therapeutics, Inc. (TVTX): Price and Financial Metrics


Travere Therapeutics, Inc. (TVTX): $22.20

-0.31 (-1.38%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TVTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 506

in industry

TVTX POWR Grades


  • TVTX scores best on the Value dimension, with a Value rank ahead of 72.26% of US stocks.
  • The strongest trend for TVTX is in Growth, which has been heading down over the past 47 weeks.
  • TVTX's current lowest rank is in the Momentum metric (where it is better than 9.67% of US stocks).

TVTX Stock Summary

  • Over the past twelve months, TVTX has reported earnings growth of 134.44%, putting it ahead of 84.45% of US stocks in our set.
  • The volatility of Travere Therapeutics Inc's share price is greater than that of 87.26% US stocks with at least 200 days of trading history.
  • Travere Therapeutics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -16.57%, greater than the shareholder yield of just 15.14% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Travere Therapeutics Inc are MX, LMNL, MRCY, CIEN, and RBBN.
  • Visit TVTX's SEC page to see the company's official filings. To visit the company's web site, go to www.retrophin.com.

TVTX Valuation Summary

  • TVTX's EV/EBIT ratio is -6.7; this is 122.87% lower than that of the median Healthcare stock.
  • TVTX's price/sales ratio has moved NA NA over the prior 106 months.
  • Over the past 106 months, TVTX's price/earnings ratio has gone down 4.3.

Below are key valuation metrics over time for TVTX.

Stock Date P/S P/B P/E EV/EBIT
TVTX 2021-08-31 6.5 4.0 -5.6 -6.7
TVTX 2021-08-30 6.4 3.9 -5.5 -6.6
TVTX 2021-08-27 6.4 3.9 -5.5 -6.6
TVTX 2021-08-26 6.2 3.8 -5.3 -6.5
TVTX 2021-08-25 6.2 3.8 -5.3 -6.4
TVTX 2021-08-24 6.1 3.7 -5.2 -6.3

TVTX Growth Metrics

  • The year over year price growth rate now stands at 41.99%.
  • The 2 year net income to common stockholders growth rate now stands at -56.14%.
  • Its 4 year price growth rate is now at 11.07%.
Over the past 18 months, TVTX's revenue has gone up $28,808,000.

The table below shows TVTX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 204.146 -27.113 -237.05
2021-03-31 197.959 -40.062 -224.106
2020-12-31 198.321 -42.743 -169.431
2020-09-30 194.025 -33.365 -78.068
2020-06-30 187.259 -54.221 -92.009
2020-03-31 183.536 -66.877 -104.642

TVTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TVTX has a Quality Grade of C, ranking ahead of 37.5% of graded US stocks.
  • TVTX's asset turnover comes in at 0.291 -- ranking 156th of 677 Pharmaceutical Products stocks.
  • MTEX, ASRT, and RIOT are the stocks whose asset turnover ratios are most correlated with TVTX.

The table below shows TVTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.291 0.968 -0.396
2021-03-31 0.289 0.968 -0.412
2020-12-31 0.311 0.969 -0.361
2020-09-30 0.304 0.970 -0.166
2020-06-30 0.303 0.967 -0.194
2020-03-31 0.301 0.970 -0.210

TVTX Price Target

For more insight on analysts targets of TVTX, see our TVTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.71 Average Broker Recommendation 1.25 (Strong Buy)

TVTX Stock Price Chart Interactive Chart >

Price chart for TVTX

TVTX Price/Volume Stats

Current price $22.20 52-week high $33.09
Prev. close $22.51 52-week low $12.75
Day low $21.66 Volume 722,908
Day high $22.99 Avg. volume 906,407
50-day MA $17.85 Dividend yield N/A
200-day MA $22.20 Market Cap 1.35B

Travere Therapeutics, Inc. (TVTX) Company Bio


Travere Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on identifying, developing, and delivering therapies to people living with rare disease. Travere Therapeutics serves customers worldwide.


TVTX Latest News Stream


Event/Time News Detail
Loading, please wait...

TVTX Latest Social Stream


Loading social stream, please wait...

View Full TVTX Social Stream

Latest TVTX News From Around the Web

Below are the latest news stories about Travere Therapeutics Inc that investors may wish to consider to help them evaluate TVTX as an investment opportunity.

Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand

ST. GALLEN, Switzerland & SAN DIEGO, Calif., September 16, 2021--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915005966/en/

Yahoo | September 16, 2021

Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand

Vifor Pharma obtains exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand Travere receives a $55 million upfront payment and is eligible for additional regulatory and commercial milestones, as well as tiered royalties on net sales Sparsentan is a potential first-in-class treatment to address significant unmet medical needs in rare kidney disorders focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) SAN DIEGO and ST GALLEN, Switzerland, Sept. 15,

Yahoo | September 15, 2021

Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of Directors

Ms. Williams-Brinkley brings more than 35 years of executive leadership experience in healthcare to the Travere BoardSAN DIEGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the appointment of Ruth Williams-Brinkley to the Company’s Board of Directors, effective immediately. Ms. Williams-Brinkley brings to Travere more than 35 years of executive leadership in care delivery and health plan operations. “On behalf of the Board of Directors, I am please

Yahoo | September 14, 2021

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on September 10, 2021, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,100 shares of its common stock to five new employees, consisting of inducement stock options to purchase an aggregate of 40,500 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 7,600 shares of its common sto

Yahoo | September 13, 2021

Travere Therapeutics Announces Successful Outcome from Type A Meeting with U.S. FDA for Sparsentan in Focal Segmental Glomerulosclerosis

Company and FDA align on a pathway to proceed with submission for accelerated approval in mid-2022 pending additional eGFR dataSAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced a successful outcome from the Company’s Type A meeting with the U.S. Food and Drug Administration (FDA) in which alignment was reached on the Company’s plan to submit additional estimated glomerular filtration rate (eGFR) data from the ongoing pivotal Phase 3 DUPLEX St

Yahoo | September 7, 2021

Read More 'TVTX' Stories Here

TVTX Price Returns

1-mo 9.96%
3-mo 48.99%
6-mo -6.09%
1-year 9.63%
3-year N/A
5-year N/A
YTD -18.55%
2020 91.94%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8303 seconds.